Ovid Therapeutics Inc risk profile
39 Normal where most of the sector sits
Measured 1 September 2026 from OVID's filed statements. Recomputed nightly.
39 (Normal), driven by Leverage and coverage at 69, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 49 | Elevated | Volatile | One-year price volatility — 87.1% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -1,201.7 percentage points |
| Cash conversion | 47 | Elevated | Easing | Free-cash-flow margin — -528.6% |
| Leverage and coverage | 69 | Stretched | Worsening | Net debt to EBITDA |
| Competitive position | 45 | Elevated | Stable | Operating-margin gap against peers — -574.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Ovid Therapeutics Inc